AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 191 min read$GH

Guardant, Geo, Tower, TG, GigaCloud Insider Shake

Insiders at Guardant Health (GH), Geo Group (GEO), Tower Semiconductor (TSEM), TG Therapeutics (TGTX), and GigaCloud (GCT) sold shares. GH saw $3.3M in sales from five insiders. GEO's SVP sold $371K, TSEM's director sold $49K, TGTX's director sold $275K, and GCT's director sold $158K.

Original reporting
tipranks.com
Published Sep 19, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 6:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guardant, Geo, Tower, TG, GigaCloud Insider Shake — source image
Source · tipranks.com
Decision brief

The 30-second read

$GHBearishLow
01

Why it matters

Provides traders with fresh Form 4 data to assess short‑term sentiment.

02

Market read

Insider sales may signal short‑term price pressure for each ticker.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 3/10Timing: recent Form 4 filings

Background

Aggregated insider sales reported for five publicly traded companies.

Company-level read

Ticker impact

$GHBearishMedium confidence
Context

Director Tariq Musa sold 116 shares for $20,300, indicating insider selling pressure.

Expected impact

modest downside risk in near term

Evidence & confidence

Director-level sell of $20k is small but adds to cumulative insider offloading.

$GEOBearishMedium confidence
Context

SVP Matthew Albence sold 11,797 shares for $371,015, a notable insider divestment.

Expected impact

potential short-term dip

Evidence & confidence

Sale exceeds $300k, suggesting material insider sentiment shift.

$TSEMNeutralHigh confidence
Context

Director Yoav Chelouche sold 232 shares for $49,893, a modest insider disposition.

Expected impact

little to no impact

Evidence & confidence

Small dollar amount relative to market cap.

$TGTXBearishMedium confidence
Context

Director Laurence Charney sold 5,000 shares for $274,800, adding to insider selling trend.

Expected impact

slight downside pressure

Evidence & confidence

Half‑million dollar sale is material for a small‑cap biotech.

$GCTBearishMedium confidence
Context

Director Zhiwu Chen sold 3,000 shares for $158,010, continuing insider offloading.

Expected impact

moderate short‑term downside

Evidence & confidence

Sale size is notable for the company's market size.

Market effects

Sector

Insider selling across healthcare and tech may slightly dampen sector sentiment.

Regional

US markets only; no broader regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Insider sales may be routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Guardant Health

    Biotech firm with recent director sell.

  • Company
    Geo Group

    Private prison operator with SVP sell.

  • Company
    Tower Semiconductor

    Semiconductor manufacturer with minor insider sell.

  • Company
    TG Therapeutics

    Biotech with director sell.

  • Company
    GigaCloud Technology

    Cloud services firm with director sell.

Read at source← All news

Related articles

OCT 27
$TSEMHighAI 8/10

Tower Semiconductor’s $1.2B Profit Roadmap Faces Its Biggest Test Yet in Q3 Earnings

Tower Semiconductor (TSEM) reports Q3 earnings on November 2, with shares down 21.25% in the past month. Q2 saw record revenue of $460.08M and adjusted EPS of $0.88, prompting raised 2028 targets to $3.6B revenue and $1.2B net profit. Analysts expect Q3 EPS of $1.0663 and revenue of $522.06M, with silicon photonics (SiPho) expansion and capacity timing as key focus areas.

247wallst.com2 min
OCT 26
$TSEMHigh

TSEM Stock Pops As Semtech AI SiGe Deal Locks In Capacity

Tower Semiconductor (TSEM) stock rose 8.81% after expanding a multi-year silicon germanium manufacturing agreement with Semtech. The deal secures dedicated capacity for Semtech across TSEM's global facilities, tying TSEM to AI data center growth. TSEM trades at 16.5x sales and 8.9x book value, with $1.57B revenue and $17.95B enterprise value. The stock corrected from $258 to $179 recently, with support near $170.

stockstotrade.com3 min
OCT 23
$TGTXMedAI 8/10

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026

TG Therapeutics (TGTX) presented Phase 1 data for azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive multiple sclerosis. 89% of evaluable participants showed stable or improved disability scores at Day 90, with no high-grade toxicities observed. The study included 26 participants, with a median follow-up of 4.9 months.

elliotlakestandard.ca3 min
OCT 23
$TGTXMedAI 8/10

First reported test of engineered immune cells in progressive MS found no severe side effects.

TG Therapeutics reported initial results from a Phase 1 study of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive MS patients. No severe side effects were observed, and 89% of evaluable patients had stable or improved disability scores. Michael S. Weiss, CEO, highlighted the potential of this off-the-shelf therapy for progressive MS. The study included 26 participants with a median follow-up of 4.9 months.

stocktitan.net3 min